Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 16/20 | 0.51 |
| ▸ | SIK3 | Q9Y2K2 | 9/20 | 0.43 |
| ▸ | SIK1 | P57059 | 8/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32691528 | 0.89 | SIK2 (0.41) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL30172482 | 0.87 | SIK2 (0.44) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL32691396 | 0.84 | SIK2 (0.40) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL32691478 | 0.84 | SIK2 (0.39) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL32691486 | 0.82 | GRM5 (0.41) | SIK2EZH2 | |
| SCHEMBL32691415 | 0.81 | SIK2 (0.35) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL32691501 | 0.81 | SIK2 (0.51) | SIK2SIK3SIK1RIPK2ABL1 | |
| SCHEMBL28585838 | 0.81 | MEN1 (0.46) | SIK2SIK3SIK1CSF1R | |
| SCHEMBL32691329 | 0.80 | SIK2 (0.38) | SIK2SIK3SIK1EZH2 | |
| SCHEMBL32691480 | 0.80 | SIK2 (0.34) | SIK2CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | ONCO3R THERAPEUTICS BV (BE) | 2026-04-21 | — | — | US | disclosed |
| EP-4724431-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF | Beone Medicines I GmbH (CH) | 2026-04-15 | — | — | EP | disclosed |
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-03-26 | — | — | US | disclosed |
| WO-2023066204-A1 | SIK INHIBITOR, COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-115448881-A | Heteroaryl compound, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115197208-A | Heteroaryl compound, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-07-28 | — | — | US | disclosed |
| WO-2020239660-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | SIK1, CHUK, SIK2 | SIK2 3/4885SIK3 5/4885SIK1 1/4885 |
| US-20220235048-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1A, IFNG, COL1A1 | SIK2 4505/4885SIK3 3536/4885SIK1 4093/4885 |
| US-12606554-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | IL23R, IL2, IL36G | SIK2 3971/4885SIK3 3243/4885SIK1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.